Hypoxia-Inducible Factor-1 as a Therapeutic Target in Endometrial Cancer Management

Table 1

Clinical trials on HIF-1α targeted therapies in endometrial cancer.

Class	Inhibitor	Mechanism	Clinical trials in endometrial cancer
Small molecule inhibitors of HIF-1
Topoisomerase inhibitor	Topotecan (topo-I)	Inhibits hypoxic induction of HIF-1α protein and DNA binding activity	Miller et al. [48] Triana et al. [49] Wadler et al. [50]
HSP90 inhibitor	Geldanamycin	Induces degradation of HIF-1α protein and inhibition of DNA binding of HIF-1	—
Other	PX-478	Inhibition of HIF-1α transcription activity	—
Inhibitors of signal transduction pathways
mTOR inhibitor	Temsirolimus (CCI-779)	Downregulation of HIF-1α by inhibing mTor	Oza et al. [51]
	Everolimus (RAD001)		Slomovitz et al. [52]
Inhibitors of HIF-1 target genes
VEGF inhibitor	Bevacizumab	Monoclonal antibody against VEGF	Aghajanian et al. [53]
CAIX inhibitor	Rencarex (WX G250)	Monoclonal antibody against CAIX	—